Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mycobacterial DNA gyrase is a type II topoisomerase enzyme essential for DNA topology maintenance in mycobacteria, including Mycobacterium tuberculosis. It is a heterotetramer (A2B2) that introduces negative supercoils into DNA, critical for replication, transcription, and chromosome segregation. It is a validated drug target for anti-tubercular agents, including fluoroquinolones and novel Mycobacterial Gyrase Inhibitors (MGIs).
Inhibition of DNA gyrase activity, leading to DNA damage and cell death. Fluoroquinolones stabilize the cleavage complex leading to double stranded breaks. MGIs induce single-stranded breaks.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterial DNA Gyrase (Gyrase).